About SUNHO BIO-B Company

We are a biopharmaceutical company dedicated to the discovery, development and commercialization of first-of-it/best-in-class biologics to regulate the immune microenvironment by directly regulating the innate and adaptive immune systems. Using our deep understanding of immunology, we have developed various types of immunotherapy, including antibody cytokines for cancer and autoimmune diseases. Our relentless commitment to innovation can be seen in our proprietary technology platforms, which include (i) the AIC platform, an expandable platform focused primarily on antibody-cytokine fusion protein development; (ii) the ADCC enhanced antibody platform (“AEA platform”), a FUT8 knockout cell line built to enhance the cytotoxicity of antibodies; and (iii) the enhanced natural immune cell polyantibody platform (“AIM platform”), a platform focused on developing bispecial/polyspecific antibodies based on innate immune stimulants. Our experienced in-house R&D team members come from diverse medical backgrounds and have rich and in-depth knowledge, which is critical to strengthening our R&D capabilities. The functions of our comprehensive R&D team cover drug discovery, in vitro evaluation, pharmacology and pharmacodynamics, protein engineering, process development, and quality analysis.